RSV
63 programs · 62 companies
Programs
63
Companies
62
Trials
39
MOAs
37
PI3KiWEE1iAnti-AβGLP-1/GIPBTKiSTINGagFXIaiCAR-T CD19IL-17iCDK2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Preclinical | SGLT2 | ||
| MRK-853 | Phase 1 | PRMT5 | ||
| ABB-8696 | Phase 3 | BCMA | ||
| AZN-5171 | Approved | GLP-1R | ||
| AZN-8281 | Phase 1 | SHP2 | ||
| SNY-5894 | Approved | CFTR | ||
| TAK-8730 | Phase 2 | VEGF | ||
| Ivosotorasib | Preclinical | CD38 | ||
| BII-4342 | Phase 2/3 | CGRP | ||
| Tirarelsin | NDA/BLA | CD19 | ||
| Cevimavacamten | NDA/BLA | Menin | ||
| Rimanesiran | Phase 1 | TIM-3 | ||
| Zenorelsin | NDA/BLA | JAK2 | ||
| CGO-2579 | Approved | TIGIT | ||
| Capirelsin | Phase 2 | FLT3 | ||
| Polalucimab | Phase 1/2 | KRASG12C | ||
| GRF-8977 | Phase 1 | FcRn | ||
| SUN-5027 | Preclinical | DLL3 | ||
| GUS-IIT-973 | Phase 2 | GPRC5D | ||
| EOR-IIT-541 | Phase 2/3 | CGRP | ||
| GIM-IIT-837 | Phase 1 | FGFR | ||
| IMM-8177 | Phase 1 | Menin | ||
| Rilutenlimab | Preclinical | B7-H3 | ||
| KRO-9986 | Phase 3 | TIGIT | ||
| Sovasotorasib | NDA/BLA | WRN | ||
| MRK-3812 | Phase 3 | CD3 | ||
| KNS-1946 | Phase 3 | DLL3 | ||
| Tiracagene | Phase 3 | SOS1 | ||
| Mirivorutinib | Phase 3 | CD38 | ||
| Olpaosocimab | Approved | SGLT2 | ||
| KAR-5490 | Phase 1 | RET | ||
| Gelituximab | NDA/BLA | CDK2 | ||
| NCN-3378 | NDA/BLA | PD-L1 | ||
| Cevimavacamten | Phase 1 | APOC3 | ||
| Zorisertib | Approved | SHP2 | ||
| STA-IIT-619 | Approved | SMN2 | ||
| PCV-5987 | Phase 2/3 | JAK2 | ||
| Adagrafutibatinib | Phase 3 | PCSK9 | ||
| MIM-9595 | Preclinical | TIM-3 | ||
| PLR-762 | Approved | JAK1 | ||
| Terazanubrutinib | Preclinical | SMN2 | ||
| Sotocapivasertib | Approved | TIGIT | ||
| NOI-8348 | Preclinical | Menin | ||
| Gozecilimab | Phase 2 | SMN2 | ||
| CUR-8000 | Phase 2 | Aβ | ||
| Sotoglumide | Phase 2/3 | MALT1 | ||
| Datocapivasertib | Phase 1/2 | B7-H3 | ||
| Gelisacituzumab | Phase 2 | C5 | ||
| Rimasacituzumab | Phase 3 | C5 | ||
| Kematinib | Phase 3 | WRN | ||
| BWA-1517 | Approved | Aβ | ||
| Tixanesiran | Phase 2 | PRMT5 | ||
| PIE-7717 | Preclinical | IL-13 | ||
| Motamavacamten | Phase 3 | BTK | ||
| Cevirelsin | Phase 2 | TYK2 | ||
| Tixacilimab | Phase 2/3 | CD3 | ||
| HET-7567 | Phase 2 | TYK2 | ||
| A-1206 | Phase 2/3 | SHP2 | ||
| ZEN-8892 | Phase 2/3 | SOS1 | ||
| STA-6220 | Phase 1 | KRASG12C | ||
| Rimanaritide | Phase 3 | CD123 | ||
| BLC-3714 | Approved | CD38 | ||
| DEC-4099 | Phase 3 | VEGF |
Trials (39)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08170862 | MRK-853 | Phase 1 | Recruiting |
| NCT05164455 | Cevimavacamten | NDA/BLA | Completed |
| NCT08635068 | Rimanesiran | Phase 1 | Recruiting |
| NCT08594730 | Zenorelsin | NDA/BLA | Active |
| NCT06986517 | GRF-8977 | Phase 1 | Terminated |
| NCT07831441 | GUS-IIT-973 | Phase 2 | Not yet recr... |
| NCT07303274 | EOR-IIT-541 | Phase 2/3 | Recruiting |
| NCT07258454 | GIM-IIT-837 | Phase 1 | Not yet recr... |
| NCT05161405 | IMM-8177 | Phase 1 | Recruiting |
| NCT04411541 | Rilutenlimab | Preclinical | Completed |
| NCT07624186 | Sovasotorasib | NDA/BLA | Completed |
| NCT04681928 | Sovasotorasib | NDA/BLA | Completed |
| NCT07541281 | MRK-3812 | Phase 3 | Not yet recr... |
| NCT08351066 | Tiracagene | Phase 3 | Not yet recr... |
| NCT08963152 | Olpaosocimab | Approved | Not yet recr... |
| NCT07091858 | Olpaosocimab | Approved | Recruiting |
| NCT03167152 | Olpaosocimab | Approved | Terminated |
| NCT05838821 | Olpaosocimab | Approved | Active |
| NCT08419930 | Gelituximab | NDA/BLA | Completed |
| NCT04118065 | Gelituximab | NDA/BLA | Active |